What's new? Log in Free sign up

Cumberland Pharmaceuticals (CPIX)

Company Profile

Company profile

Ticker

CPIX

Exchange

Website

www.cumberlandpharma.com

CEO

Mr. A. J. Kazimi MBA

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

AppTech Corp., CSI Business Finance, Inc., HEALTH EXPRESS USA INC, Natural Nutrition Inc.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

CPIX stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Vibativ® Receives Marketing Approval In China

Prospectus supplement for primary offering

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial

FDA APPROVES ACETADOTE® sNDA

Cumberland Pharmaceuticals Receives Fda

Quarterly report

8 Nov 24

Cumberland Pharmaceuticals Reports Third Quarter 2024

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

INTEGRATED CORE STRATEGIES (US) LLC

Martin S Brown JR

Joseph C Galante

Kenneth Krogulski

Financial summary

Financial statements Chart CPIX financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	17.46 mm	17.46 mm	17.46 mm	17.46 mm	17.46 mm	17.46 mm
Cash burn (monthly)	(no burn)	86.93 k	564.81 k	912.81 k	(no burn)	123.06 k
Cash used (since last report)	n/a	442.73 k	2.88 mm	4.65 mm	n/a	626.70 k
Cash remaining	n/a	17.02 mm	14.59 mm	12.82 mm	n/a	16.84 mm
Runway (months of cash)	n/a	195.8	25.8	14.0	n/a	136.8

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

CPIX institutional ownership history Ownership history

11.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	13	8	+62.5%
Opened positions	6	1	+500.0%
Closed positions	1	16	-93.8%
Increased positions	0	1	EXIT
Reduced positions	3	2	+50.0%

13F shares	Current	Prev Q	Change
Total value	1.88 bn	1.55 bn	+21.4%
Total shares	1.65 mm	1.20 mm	+38.0%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Renaissance Technologies	528.16 k	$676.05 mm	-1.9%
Vanguard	374.25 k	$479.04 mm	NEW
Dimensional Fund Advisors	284.01 k	$363.53 mm	-6.6%
Acadian Asset Management	188.16 k	$239.00 k	0.0%
BlackRock	110.07 k	$140.89 mm	NEW
BK The Bank of New York Mellon Corporation	75.27 k	$96.34 mm	0.0%
Geode Capital Management	74.31 k	$95.13 mm	-16.3%
NTRS Northern Trust	16.32 k	$20.89 mm	NEW
OAKC Oakworth Capital	3.05 k	$3.91 mm	0.0%
WFC Wells Fargo & Company	250.00	$320.00 k	NEW

Largest transactions	Shares	Bought/sold	Change
Vanguard	374.25 k	+374.25 k	NEW
BlackRock	110.07 k	+110.07 k	NEW
Dimensional Fund Advisors	284.01 k	-20.10 k	-6.6%
NTRS Northern Trust	16.32 k	+16.32 k	NEW
Geode Capital Management	74.31 k	-14.44 k	-16.3%
Renaissance Technologies	528.16 k	-10.00 k	-1.9%
Innealta Capital	0.00	-948.00	EXIT
WFC Wells Fargo & Company	250.00	+250.00	NEW
JPM JPMorgan Chase & Co.	219.00	+219.00	NEW
Advisor	100.00	+100.00	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CPIX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
20 Dec 24	Kazimi A J	Common Stock	Buy	Acquire P	No	Yes	2.35	39	91.65	5,702,296
20 Dec 24	Jones James	Common Stock	Buy	Acquire P	No	Yes	2.35	39	91.65	40,146
20 Dec 24	Young Caroline	Common Stock	Buy	Acquire P	No	Yes	2.35	2	4.70	29,818
20 Dec 24	Krogulski Kenneth	Common Stock	Buy	Acquire P	No	Yes	2.35	301	707.35	276,343
19 Dec 24	Kazimi A J	Common Stock	Buy	Acquire P	No	Yes	2.33	40	93.20	5,702,257
19 Dec 24	Jones James	Common Stock	Buy	Acquire P	No	Yes	2.33	40	93.20	40,107
19 Dec 24	Young Caroline	Common Stock	Buy	Acquire P	No	Yes	2.33	4	9.32	29,816
19 Dec 24	Krogulski Kenneth	Common Stock	Buy	Acquire P	No	Yes	2.33	266	619.78	276,042
18 Dec 24	Kazimi A J	Common Stock	Buy	Acquire P	No	Yes	2.19	49	107.31	5,702,217
18 Dec 24	Jones James	Common Stock	Buy	Acquire P	No	Yes	2.19	49	107.31	40,067

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Cumberland Pharmaceuticals And SciClone Pharmaceuticals Announced The National Medical Products Administration Approval Of Cumberland's Vibativ (Telavancin) Injection In China

Vibativ is an antibiotic for pneumonia and serious skin infectionsApproval in China paves the way for launch in world's second-largest market

Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease

Cumberland Pharmaceuticals' Phase 2 trial shows ifetroban improves heart function in Duchenne muscular dystrophy patients.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

S&P 500 Edges Lower; AutoZone Posts Downbeat Earnings

Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings

Press releases

From Benzinga Pro

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

NASHVILLE, Tenn., Feb. 25, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its annual 2024 financial results and provide a

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

Vibativ® is a life-saving antibiotic for pneumonia and serious skin infections Approval in China paves the way for launch in world's second-largest market NASHVILLE, Tenn. and SHANGHAI, Feb. 18, 2025

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

NASHVILLE, Tenn., Feb. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced

Stocks to Watch in December 2025: LDTC, CPIX, PNPN.V, ZEO, and More Inside

FDA APPROVES ACETADOTE® sNDA

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.